MedTrace Logo

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study

NCT01203748 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 589

Last updated 2019-01-30

No results posted yet for this study

Summary

This investigation is designed with the hypothesis that combined PV Antral Isolation and Ablation of Complex Fractionated Electrograms (PVI+CFE) approach will offer a higher success rate compared to the Wide Circumferential Pulmonary Vein Antrum Isolation (PVI) approach and to the Combined PV Antral Isolation and Empiric Linear Ablation (PVI+Lines) approach.

Conditions

Interventions

PROCEDURE

PVI + Lines ablation

Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)

PROCEDURE

PVI

Pulmonary vein antrum isolation

PROCEDURE

PVI + CFE ablation

Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Atul Verma, Dr. · Southlake Regional Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203748 on ClinicalTrials.gov